News stories about "Eli" in India.

Investors increase holdings of weight-loss drug makers’ shares in Q3 -filings

Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly (LLY.N) and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday. Key Points

Reuters

At 9 months, Hamas’ youngest hostage had just begun crawling

Kfir Bibas is the youngest of roughly 240 hostages—including 32 children—held by Hamas. Nine months old. The smiling red-haired baby had recently started to crawl after rocking on all fours. Kfir Bibas lived with his parents and 4-year-old brother in a kibbutz in southern Israel. Key Points

The Tribune India

Eli Lilly plans new 2 billion euro German plant

U.S. pharmaceuticals company Eli Lilly (LLY.N) plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros Key Points

Reuters

Lilly to build $2.5 bln diabetes drug plant in Germany

Eli Lilly (LLY.N) will build its first plant in Germany for 2.3 billion euros ($2.5 billion) in the western town of Alzey, the U.S. pharmaceuticals maker said on Friday, as the sector scrambles to meet demand for new diabetes and obesity therapies. Key Points

Reuters

Boy Swallows Universe: Check out the trailer, release date, cast and other details

The upcoming Netflix series, Boy Swallows Universe is based on the best-selling novel by Trent Dalton and stars Felix Cameron as Eli Bell, the protagonist. Here's everything to know about the release date, trailer, cast and other details. Key Points

Economic Times

Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund

Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N), aiming to tap into growing demand for their weight-loss and diabetes drugs. Key Points

Reuters

Retail investors crowd into Eli Lilly after weight-loss drug approval

Retail flows into Eli Lilly (LLY.N) spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, when Zepbound was cleared in the U.S. and the U.K., hitting their highest levels since January 2021, as per data from Vanda Research. Key Points

Reuters

Britain to study weight loss drug's potential to get people back to work

Britain is set to explore the potential of Eli Lilly's weight loss drug to improve public health and economic productivity by reducing long-term sickness. Health minister Wes Streeting believes this initiative, supported by substantial investment and research, could significantly impact obesity management and alleviate NHS demands. Key Points

India Today

Patients on Lilly's Zepbound regain weight after stopping treatment - study

Patients on Eli Lilly's (LLY.N) weight-loss drug substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday. Key Points

Reuters

Eli Lilly's obesity drug now available in U.S. pharmacies

Eli Lilly's (LLY.N) recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost customers whose health insurance does not cover the drug $550 a month, or half the list price, the company said on Tuesday. Key Points

Reuters

Lilly's bowel disease drug gets US FDA nod for treatment in adults

Eli Lilly and Co (LLY.N) said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderate-to-severe active ulcerative colitis, a type of chronic inflammatory bowel disease. Key Points

Reuters

Eli Lilly settles whistleblower lawsuit over manufacturing problems

Eli Lilly and Co (LLY.N) and a former employee agreed to settle a lawsuit in which the worker claimed she was terminated after pointing out poor manufacturing practices and data falsification involving one of its blockbuster diabetes drugs, according to court filings. Key Points

Reuters

Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion

Amphastar Pharmaceuticals will buy Baqsimi from Eli Lilly and Co in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday. Key Points

Reuters